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 Abstract: 
Introduction 
Excessive bleeding after cardiopulmonary bypass (CPB) is risk factor for adverse outcomes 
after elective cardiac surgery (ECS). Differentiating between patients who bleed due to 
surgical issues and those whose excessive chest tube output (CTO) is due to coagulopathy, 
remains challenging. Bedside suitable tests to identify hemostatic disturbances and predict 
excessive bleeding are desirable. The study sought to evaluate prediction of excessive 
bleeding after ECS using two bedside suitable devices for platelet function and viscoelastic 
blood clot properties assessment. 
Methods 
We enrolled 148 patients (105 male and 43 female) undergoing ECS in a prospective 
observational study. Patients were characterized as bleeders if their 24 hour CTO exceeded 
the 75
th
 percentile of distribution. Multiple electrode aggregometry (MEA, with ASPI, ADP 
and the TRAP test) and rotational thromboelastometry (TEM, with ExTEM, HepTEM and 
FibTEM test), were performed at three time points: preoperatively (T1), during CPB (T2), and 
after protamine administration (T3). The primary endpoint was CTO and the secondary 
endpoint was administration of blood products, 30-day and 1 year mortality. 
Results 
The best predictors of increased bleeding tendency were the tests performed after protamine 
administration (T3). At T3, patients characterized as bleeders had significantly lower MEA 
ASPI (median, 14 vs. 27 AUC, p=0.004) and ADP test values (median, 22 vs. 41 AUC, 
p=0.002) as well as TEM values expressed in maximum clot firmness after 30 min (MCF 30) 
for ExTEM (53 vs. 56 mm, p=0.005), HepTEM (48 vs. 52 mm, p=0.003) and FibTEM (8 vs. 
11 mm, p<0.001) test. 24 hour CTO inversely correlated with both the MEA (ASPI test: r=-
0.236, p=0.004; ADP test: r=-0.299, p<0.001), and TEM MCF 30 (ExTEM: r=-0.295, 
p<0.001; HepTEM: -0.329, p<0.001; FibTEM: -0.377, p<0.001) test values. 
Conclusion 
Our study showed that MEA and TEM are useful methods for prediction of excessive 
bleeding after ECS. In order to prevent excessive postoperative CTO, hemostatic 
interventions with timely and targeted blood component therapy according to MEA and TEM 
results should be considered. 
Keywords: multiple electrode aggregometry; rotational thromboelastometry; cardiac surgery; 
bleeding risk; transfusion 
 Introduction: 
Cardiac surgery procedures with cardiopulmonary bypass (CPB) are often accompanied with 
an increased bleeding tendency. For these patients bleeding into the chest remains a common 
life-threating complication[1]. Excessive bleeding after CPB continues to be an important 
cause of morbidity and mortality[2]. Dixon B et al[3] reported chest tube output (CTO) as the 
strongest independent predictor of mortality[3]. Excessive hemorrhage results in the 
transfusion of allogenic blood products that expose the patient to multiple risks [4-6].  
Disturbances of coagulation consequent to CPB have a multifactorial etiology, such as loss of 
platelet reactivity, coagulation factor consumption, hemodilution due to the CPB priming 
procedure etc.[7]. Extracorporeal circulation and heparin may induce many abnormalities in 
the coagulation system, including thrombocytopenia[2], platelet dysfunction[8, 9], 
coagulation factor deficiencies[10], residual heparin after protamine administration[11], and 
fibrinolysis[12]. Microvascular bleeding caused by dysfunctional platelets and an impaired 
coagulation cascade occur after CPB secondary to foreign surface contact[13]. Impaired 
platelets removed from the CPB circuit are presumed to be dysfunctional and are jointly 
responsible for postoperative bleeding [13].  
However, the question „How to predict and prevent excessive postoperative bleeding?“ 
remains challenging. Differentiating between coagulopathy and inadequate surgical 
hemostasis as a cause for bleeding after CPB is sometimes difficult. Identifying abnormal 
alteration of platelet function and coagulation tests prior to and after CPB may make the 
important differentiation between coagulopathic (nonsurgical) bleeding requiring 
procoagulant blood components transfusion and surgical bleeding requiring surgical 
intervention. Reliable methods to predict patients with higher risk of coagulation impairments 
are lacking [14]. Conventional coagulation tests are not able to predict postoperative bleeding 
[15, 16]. „Blind“ transfusion therapy with multiple blood products still occurs when bleeding 
is excessive, and transfusion of allogeneic blood products expose patients to multiple risks 
and increased expenses[4, 17-20]. The bedside suitable tests with capability for differentiating 
bleeders from nonbleeders would be useful in creating a transfusion algorithm to guide blood 
product targeted therapy. Rotation thromboelastometry (TEM) performed on whole blood 
samples provides information on the contribution of fibrinogen and platelets to clot formation. 
A significant reduction in the number of blood transfusions and mediastinal re-exploration for 
hemorrhage in cardiac surgery patients after institution of thromboelastography-guided blood 
product administration is described in retrospective study by Spiess et al[21]. Despite the fact 
that thromboelastometry use resulted in procoagulant blood products administration 
reduction, the precise relationship between thromboelastometry values and postoperative 
bleeding still remains unclear. Although obtaining evidence about the global coagulation 
cascade, this method is inaccurate for detecting isolated platelet dysfunction. Therefore, it 
seems that simultaneous use of TEM and platelet function assay could offer a comprehensive 
insight into the hemostatic properties. Multiple electrode aggregometry (MEA) uses the 
technique of whole blood aggregometry and quantifies platelet function by attachment of 
platelets activated with different stimulants onto metal electrodes leading to increase of 
electrical impedance.  
This study sought to evaluate whether perioperative viscoelastic blood properties and platelet 
function measurements in three intraoperative measurement time points using concomitant 
TEM and MEA can identify patients with increased bleeding risk as measured by 
postoperative blood loss. We were also interested to determine whether above mentioned two 
Point of Care (POC) devices can predict patients at enhanced risk of blood products 
administration due to excessive blood loss. We hypothesized that MEA and TEM could detect 
patients with higher risk of excessive postoperative bleeding and transfusion requirements.
 Patients and methods:  
Patient selection: 
This prospective observational study was approved by the Institutional Research Ethics 
Review Board and registered at the Clinical-trials.gov website (Identifier NCT01281397). 
Type and daily dose of antiplatelet therapy (APT), received preoperatively, and the interval 
from the last dose of clopidogrel (CLO) to surgical procedure was documented. 
After approval by the local Medical University and University Hospital Center Ethics 
Committee and written informed consent, 148 consecutive patients (male, n=105 (70.9%); 
female, n=43 (21.9%)), scheduled for elective cardiac surgery (ECS) procedures requiring 
cardiopulmonary bypass (CPB) between July 2010 and January 2011 were prospectively 
studied. Criteria for excluding patients from the group of subjects were: age younger than 18 
years, urgent procedure, patients with off-pump cardiac surgical procedure, on APT other than 
Aspirin (ASA) and CLO, patients with inaccurate APT administration documentation, urgent 
surgery, and patients requiring surgical exploration for excessive bleeding due to obvious 
surgical bleeding with a bleeding vessel identified. 
In our study cohort APT was administered by the referral cardiologist. If patients were 
admitted to Department of Cardiac Surgery with a daily dose of 100 mg ASA, the drug was 
continued up to the day of surgery. If patients were admitted with a daily dose of 75 mg CLO, 
either alone or in addition to ASA, CLO was discontinued at Department of Cardiac Surgery 
prior to surgery with different time intervals from CLO cessation to surgery, from 2 to 8 days, 
respectively. Time from CLO cessation to surgery varied individually, based on the date of 
admission to Department of Cardiac Surgery and the date of the procedure. Patients received 
APT continuously for at least 10 days prior to admission to our department. 
 Perioperative management:  
All patients had the same anesthetic and perfusion teams, and were admitted at least 1 day 
before surgery. Surgery was performed by using a standard technique. Surgical approach in 
all cases was through median sternotomy. All measurements were performed by research 
fellow, not directly included in treating patients. The nurses, anesthesiologists, and surgeons 
managing the patient's care were blinded to the both, TEM and MEA results. Surgery was 
performed in a single unit with standard surgical techniques. Surgical bleeding was controlled 
with diathermy and bone wax.  
Cardiopulmonary circuit consisted of the Medtronic Affinity Trillium membrane oxygenator, 
venous reservoir and PVC tubing (Medtronic, Minneapolis, MN, USA) and a Stoeckert III 
roller pump (Stoeckert, Munich, Germany). Flow at 2.2 l min-1 m-2 and mean blood pressure 
of 60 mmHg were targeted. Heart was arrested with cold blood cardioplegia. Systemic 
heparinisation aiming at an activated clotting time (ACT) >480 s was used, followed by full 
reversal with protamine after decannulation. A dose of 1 g tranexamic acid was given at the 
induction of anesthesia and after protamine administration. Inotropic support was initiated in 
order to maintain a cardiac index greater than 2.2 l min-1 m-2. Weaning from CPB was 
initiated once the patient’s rhythm had stabilized and normothermia had been achieved. 
Cardiotomy suction returned blood to the CPB circuit. Packed red blood cells (PRBC) were 
transfused if hematocrit was <20% during CPB and < 25% after terminating CPB, or when 
significant bleeding was obvious. Volume replacement in the intensive care unit was 
administered as deemed necessary by the attending physician using hydroxyethyl starch 6% 
130/0.4 and lactated Ringer's solution, PRBC's were transfused if deemed necessary by the 
consultant anesthesiologist. 
Fresh frozen plasma (FFP) was given in cases showing prolonged prothrombin time (less than 
45%), or according to clinical decision by the consultant anesthesiologist. Fibrinogen 
cryoprecipitate and platelet transfusion were administered in cases of excessive bleeding at 
discretion of consultant anesthesiologist.  
Blood Sampling: 
Blood samples for MEA and TEM measurements were obtained at three time points on day of 
surgery via central venous port. For MEA tests blood was collected in 4 ml heparin (Lithium 
Heparin 68 I.U.) coated BD Vacutainer
®
 plastic tubes. For TEM test blood was collected in 
1.8 mL sodium citrate (0.109Molar/3.2% citrate concentration) Vacutainer
®
 plastic tubes. 
Routine laboratory tests were performed each day from day before surgery to fourth 
postoperative day. The same person, not directly involved in patient care, performed all 
measurements. Blood samples for MEA were at rest for 30 minutes after blood withdrawal 
and MEA was performed subsequently. TEM tests were performed immediately after blood 
withdrawal. 
To assess changes in viscoelastic blood properties and platelet function before, during and 
after CPB, samples were drawn before induction of anesthesia (T1), after release of aortic 
clamp (T2), and 15 min after heparin neutralization (T3). 
We used two point of care (POC) devices for platelet function assessment and for monitoring 
of viscoelastic properties of blood clot. 
Multiple electrode aggregometry (MEA): 
Whole blood aggregation was determined using a new generation impedance aggregometer 
(Multiplate
®
 analyzer, Dynabyte Medical, Munich). Detailed description of method has 
already been published [22]. Put briefly, MEA is based on the principle that blood platelets 
are non-thrombogenic in their resting state, but expose receptors on their surface when they 
get activated, which allow them to attach on vascular injuries and artificial surfaces. When 
platelets stick on the Multiplate sensor wires, they enhance the electrical resistance between 
them, which is continuously recorded. Increase in impedance is expressed in arbitrary area 
under curve (AUC) units, highlighted as the parameter with the highest diagnostic power [22, 
23]. Platelet aggregation was determined in response to stimulation with arachidonic acid with 
a final concentration of 0.5 mM (ASPI test designed to evaluate ASA effect) , adenosine 
diphosphate (ADP) with a final concentration of 6.4µM (ADP test designed to evaluate 
thienopyridines, such as CLO, effect) and thrombin receptor-activating peptide (TRAP-6), 
TRAP test, 32- µM final concentration. The TRAP test is sensitive to GPIIb-IIIa inhibitors 
only, and in absence of these drugs, represents the „natural“ aggregation potential of the 
platelets. 
Modified rotational thromboelastometry (TEM): 
TEM was performed according to the manufacturer' instruction using equipment and kits 
provided by TEM International GmbH, Munich, Germany. The following kits were used: 
intrinsically activated coagulation (InTEM) and extrinsically activated coagulation (ExTEM), 
which induce clot formation via the intrinsic pathway or the extrinsic, tissue-factor-dependent 
pathway, respectively; HepTEM assay (heparinase modified TEM), coagulation is triggered 
via the intrinsic pathway. FibTEM, a test measuring the contribution of fibrinogen, which is 
based on ExTEM but contains cytochalasin D to inhibit the contribution of platelets in order 
to give a measure for the contribution of fibrinogen to clot firmness. By digital data 
processing, the following typical variables are obtained: clotting time (CT), the time from the 
start of measurement until the onset of clotting; Clot formation time (CFT), the time between 
the onset of clotting and the moment when the clot firmness reaches an amplitude of 20 mm; 
A 10, A 20, A 30 corresponds to the maximum amplitude of the curve after 10, 20 and 30 
minutes, respectively. 
Primary and secondary outcome definition and evaluation: 
Chest tube output (CTO) was determined as study's primary outcome. To estimate blood loss, 
we meticulously documented CTO, in first 24 postoperative hours and divided it by patient’s 
weight. Drainage loss was assessed after completion of a 30-minute stabilization period. 
Blood loss during the stabilization period was not included in the definition of postoperative 
hemorrhage. Such loss may be caused by postural changes when transferring the patient from 
the operating room table to the bed or because of fluid in the pleural or mediastinal cavity, 
which may have arisen from the rinsing with water as an attempt to achieve surgical 
hemostasis. Intraoperative and postoperative transfusion requirements (PRBC in mL, FFP in 
mL, fibrinogen cryoprecipitate in grams and platelet concentrates in units) were determined as 
study's secondary outcome. Surgical reexploration of the mediastinum for excessive bleeding 
was noted, along with any surgical explanation for the bleeding. 
Although some authors offer definitions of abnormal blood loss[16], we decided to make our 
own definition in order to adapt the volume of postoperative CTO to our study cohort. We 
believe that such a definition makes the most reliable correlation, and is not distorted to 
different perfusionistic, surgical and anesthetic techniques described by other authors. 
Postoperative CTO was recorded for the first 24 postoperative hours and divided by the 
patient’s weight. Patients were characterized as bleeders if their 24 hour CTO (ml/kg) 
exceeded > 75
th 
 percentile of distribution. A similar definition has already been described in 
the literature[24]. MEA and TEM variables were correlated to 24 hour CTO (ml/kg). Patients 
were divided with respect to presence of excessive bleeding, and MEA and TEM variables 
were compared between groups. 
Statistical analysis: 
The Kolmogorov-Smirnov test was used for evaluating the normality of distribution of all 
continuous variables. Correlation between CTO during the first postoperative 24h and MEA 
parameters was evaluated by Spearman's correlation coefficient. Mann-Whitney U test was 
used to evaluate whether the medians on a test variables differ significantly between two 
groups. Chi-square statistic test was used to compare a frequency distribution of observed 
categoric variables between the two groups. Receiver operating characteristic curve (ROC) 
was constructed to assess the ability of MEA and TEM parameters to predict excessive 
postoperative blood loss [25]. A value of p<0.05 was considered statistically significant. For 
statistical analysis we used MedCalc
®
 For Windows (MedCalc Software, Broekstraat 52, 
9030 Mariakerke, Belgium). 
 Results: 
All patients from sample were discharged from hospital. 24 hour CTO value of 12.46 ml/kg 
presented 75
th 
percentile of distribution, thus cut off value for “bleeder category”. The cohort 
group was divided into two subgroups according to occurrence of excessive postoperative 
bleeding. Patient's demographic, surgical, and baseline routine laboratory findings are 
presented in Table 1a and 1b. Differences in clinical and transfusion outcomes of patient 
groups according to bleeding tendency are presented in Table 2. Higher proportion of patients 
in “bleeder” category were preoperatively exposed to CLO (43.2% vs.22.5% , p=0.015, Table 
1b). For patients exposed to CLO preoperatively, we observed shorter timeframe from 
clopidogel discontinuation to surgery in “bleeder” group (4 vs. 6 days, p= 0.024).  
Two groups according to excessive bleeding occurrence were compared for clinical and 
transfusion outcomes (Table 2.). In „excessive bleeding“ subgroup, higher proportion of 
patients were transfused with fresh frozen plasma (43.2% vs. 12.6%, p<0.001), fibrinogen 
concentrate (24.3% vs. 1.8% , p<0.001), and platelet concentrate (10.8% vs. 1.8% , p=0.016). 
Concerning clinical outcome, 1 year mortality was more frequently observed in „excessive 
bleeding“ subgroup (12.1% vs. 1.9% , p=0.012). 
Comparison of MEA and TEM test results between „bleeder“ and „non-bleeder“ category and 
correlation of MEA and TEM values with CTO is presented for each time point in Table 3a 
(T1), 3b (T2) and 3c (T3), respectively. 
At T1, significant differences between groups were found for MEA ASPI test (Median 20 vs. 
40 AUC, p=0.043) and FibTEM A 20 (Median 16 vs. 18 mm, p= 0.044) (Table 3a). MEA 
ASPI test (p=0.019), InTEM A 20 (p=0.038), InTEM A 30 (p=0.035),  FibTEM A 10 
(p=0.021), FibTEM A 20 (p=0.01) and FibTEM A 30 (p=0.019) significantly correlated to 24 
hour CTO. 
At T2, significant differences between groups were found for MEA ASPI and ADP test 
values, as well as for HepTEM, ExTEM and FibTEM variables (Table 3b). 
The best predictors of increased bleeding tendency were the tests performed after protamine 
administration (T3) (Table 3c). At T3, patients characterized as bleeders had significantly 
lower MEA ASPI (median, 14 vs. 27 AUC, p=0.004) and ADP test values (median, 22 vs. 41 
AUC, p=0.002) as well as TEM values expressed in maximum clot firmness after 30 min 
(MCF 30) for ExTEM (53 vs. 56 mm, p=0.005), HepTEM (48 vs. 52 mm, p=0.003) and 
FibTEM (8 vs. 11 mm, p<0.001) test. 24 hour CTO inversely correlated with both the MEA 
(ASPI test: r=-0.236, p=0.004; ADP test: r=-0.299, p<0.001), and TEM MCF 30 (ExTEM: r=-
0.295, p<0.001; HepTEM: -0.329, p<0.001; FibTEM: r=-0.377, p<0.001) test values. 
At T3, both the MEA and TEM tests with the strongest correlations to 24 hour CTO were 
tested for accuracy in predicting excessive postoperative bleeding using ROC analysis. The 
accuracy of the ASPI test (AUC 0.636, p=0.008) is shown in Figure 1, the accuracy of the 
ADP test (AUC 0.667, p=0.001) is shown in Figure 2, the accuracy of the ExTEM alfa (AUC 
0.691, p<0.001) is shown in Figure 3, the accuracy of the FibTEM A 30 (AUC 0.695, 
p<0.001) is shown in Figure 4, and the accuracy of the HepTEM A 30 (AUC 0.663, p=0.002) 
is shown in Figure 5. We used ACT test regularly after protamine administration. We 
compared ACT values between groups with respect to bleeding tendency and we found non-
significant differences between groups (median 137 vs. 138 sec, p=0.755). In addition to, 
ACT value did not correlate to value of 24 hour chest tube output (Spearman’s correlation 
coefficient -0.002, p=0.976). 
 Discussion: 
Our study showed that MEA and TEM are useful methods for prediction of excessive 
bleeding after ECS. The best predictors of increased bleeding tendency were the tests 
performed after protamine administration (T3). One reason for such results is the fact that the 
effect of CPB on platelet function and viscoelastic blood properties and the consequent risk of 
bleeding were not explored in T1. 
Hemostatic impairment after CPB is complex in nature due to many components of the 
hemostatic system involved in. In addition to insufficient surgical hemostasis, bleeding after 
CPB may be induced by many abnormalities in the coagulation system. Conventional 
laboratory tests are unable to decompose multifactorial coagulopathy pathogenesis as 
described by Paparella et al[26]. Impaired platelet function is thought to be the most common 
coagulation defect associated with CPB[2, 27]. In the absence of platelet mapping, both 
thromboelastometry and thromboelastography are poor indicators  of impaired platelet 
function. Thus, concurrent use of both modified rotational thromboelastometry (TEM) and  
MEA should be the best show of hemostatic properties of blood. 
Literature review 
Conflicting data have been reported regarding ability of point-of-care clotting assays and 
platelet function assays to predict bleeding after cardiac surgery procedures. 
Essel et coworkers [28] compared conventional thromboelastography to conventional 
coagulation tests. Whilst the bleeding time and platelet count had sensitivities similar to 
thromboelastography, thromboelastography specificity was greater. In addition, they 
suggested that patients with abnormal thromboelastography were at increased risk of bleeding 
but the excessive bleeding in the face of a normal thromboelastography implied surgical 
bleeding and FFP and platelets should not simply be used empirically[28]. 
Analyzing patients with coronary artery bypass surgery (CABG), Ti et al found moderate 
correlation between thromboelastography parameters, total blood loss and blood product 
requirements in „bleeders“ cohort subgroup[29]. The major drawback of this study was the 
fact only CABG surgery patients were evaluated.  CABG surgery patients differ from patients 
undergoing  „other than isolated CABG“ surgery in the use of anticoagulants, length of CPB, 
age of patients and preoperative status. Mengistu et al showed that patients requiring 
postoperative blood transfusion showed lower preoperative ADP-mediated aggregometry 
compared with nontransfused patients, whereas thromboelastography did not show 
differences preoperatively[14]. Contrary to results reported by Mengistu et al [14], 
comparison of patient groups with respect to transfusion requirements in our study revealed 
no differences in T1 MEA test values. However, transfuded patients had significantly lower 
T1 values of InTEM, ExTEM and FibTEM values. Forrestier et al showed decreased ADP-
mediated platelet aggregation in patients with increased bleeding tendency after cardiac 
surgery[30]. Our results suggest similar phenomenon for ADP test values in T2 (Spearman r = 
-0.230, p=0.005) and T3 (Spearman r = -0.299, p<0.001), but not in T1 time point where ADP 
test value did not correlate to CTO volume (Spearman r = -0.095, p=0.252). Ray et al reported 
extensive bleeding in patients with reduced preoperative platelet aggregation[31]. This report 
is only partially in line with our results. Preoperatively (T1) significant differences between 
groups with respect to bleeding tendency were found for MEA ASPI test (Median 20 vs. 40 
AUC, p=0.043), but not for ADP and TRAP test. 
In contrast to our results, several studies found no correlation between clotting assays and 
bleeding outcomes.  Nutall et al described post CPB bleeding prediction using 
thrombelastography. The thromboelastography values that were most sensitive and specific 
for differentiating bleeding from nonbleeding patients were within the normal range for 
thromboelastography[32]. The major drawback was the fact that patients were characterized 
as bleeder by subjective designation of the surgical field by anesthesiologist and surgeon. Of 
note, the thromboelastography values did not correlate with blood loss.Dorman et al didn't 
find significant relationship between thromboelastography variables and blood losses[33]. 
Wang et al described similar results with lack of any correlation between 
thromboelastography variables and postoperative blood loss[34]. Ostrowski et al described 
correlation between preoperative thromboelastography data and blood product usage, but 
there was no correlation between thromboelastography data and chest tube drainage[35]. 
Cammerer et al reported risk stratification of patients with increased bleeding tendency by 
maximal clot firmness and alpha-angle, but low positive predictive values did not allow 
clinical application[24]. 
Conclusion 
In order to prevent excessive postoperative CTO, hemostatic interventions with timely and 
targeted blood component therapy according to MEA and TEM results should be considered. 
TEM can be used to predict bleeding in cardiac surgery, but it can also be used to guide 
targeted blood products transfusion algorithms where its use had been associated with 
significant decreases in blood products administration[36]. 
The inconsistent results that were obtained in the various studies could be due to differences 
in the TEM and thromboelastography tests that were applied (i.e. clotting activation via 
intrinsic or extrinsic pathway), concentration of the stimuli, as well, as due to differences in 
the recording time of blood loss [37, 38]. The definition of what constitutes abnormal 
postoperative bleeding is difficult. Although blood loss is a continuous variable, a separation 
of normal and abnormal bleeding based on single numerical value is necessary to allow 
meaningful comparisons with previous studies. Ti et al[16] described the drawbacks of chest 
tube output quantification. Blood loss measured from the chest and mediastinal tubes consists 
of a mixture of fluids, including actual blood loss, serous drainage, and fluid left in the pleural 
cavity. Also, the actual blood loss through these tubes is the sum of coagulopathic bleeding 
and surgical bleeding from wound edges which may partially explain low specificity values as 
obtained by ROC analysis. In present study, drainage loss was assessed after completion of a 
30-minute stabilization period. Blood loss during the stabilization period  may be caused by 
postural changes when transferring the patient from the operating room table to the bed or 
because of fluid in the pleural or mediastinal cavity, which may have arisen from the rinsing 
with water as an attempt to achieve surgical hemostasis. We decided to monitor chest tube 
output in first 24 hours after surgery. Drainage loss after this period was not considered to be 
of “hemostatic disturbances” origin, because it most likely originates from a surgical source 
(eg, detached arterial clip). Concerning serous drainage, chest output output observed in the 
first 24 postoperative hours in present study was never clear and serous, but sanguinary and 
accompanied with the drop in hemoglobin levels, thus indicating hemorrhage. Standard goal-
directed restrictive fluid therapy was employed in all cases. When executed meticulously, as it 
is in our institution, it is unlikely to reduce albumin to a level that could be connected with 
such a significant decline in colloid osmotic pressure in patients with preoperatively normal 
protein level (measuring protein level is a part of routine preprocedural panel of tests, albumin 
level is not).  
In our study the attending clinicians, both the anesthesiologists and surgeons were blinded to 
MEA and TEM results, therefore administering procoagulant blood products mainly on the 
clinical grounds. The use of procoagulant blood products certainly affected the number of 
bleeders and amount of bleeding. This decrease in amount of bleeding would reduce the 
degree of correlation between blood loss and both MEA and TEM parameters by increasing 
the number of false-negative results, and reducing the sensitivity of MEA and TEM 
parameters. Finally, MEA and TEM are useful in distinguishing patients by excessive 
bleeding and provide correlations with CTO. Values above the cut-off values do not imply the 
fact that the patients will not bleed, however they may advise to pay attention to surgical 
cause of bleeding. Hemostatic management algorithm with the timely and targeted 
procoagulant blood component therapy administration according to MEA and TEM should be 
evaluated in context of outcomes such as mortality, bleeding and transfusion requirements.  
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 Tables: 
Table 1:  
Basic demographic, laboratory and operative data statistics of patient groups according to 
bleeding tendency for continuous (Table 1a) and categorical (Table 1b) variables  
Table 1a: 
  24h chest 
tube 
output 
(ml/kg) 
N 
Percentiles 
Mann-
Whitney 
U 
  25th 
50th 
(Median) 
75th p 
Age (years) 
<75. 
Percentile 
111 57.00 65.00 72.00 
0.536 
>75 
percentile 
37 52.50 69.00 73.00 
Body mass index 
(kg/m2) 
<75. 
Percentile 
111 25.72 28.65 31.35 
0.266 
>75 
percentile 
37 25.22 27.77 31.06 
Body surface 
area (m2) 
<75. 
Percentile 
111 1.83 1.99 2.13 
0.136 
>75 
percentile 
37 1.77 1.89 2.11 
EURO score (%) 
<75. 
Percentile 
111 1.81 2.71 5.62 
0.844 
>75 
percentile 
37 1.81 3.78 5.52 
Ejection fraction 
(%) 
<75. 
Percentile 
111 45.00 60.00 65.00 
0.563 
>75 
percentile 
37 50.00 55.00 61.00 
Days after 
clopidogrel 
discontinuation 
<75. 
Percentile 
25 4.00 6.00 7.50 
0.024 
>75 
percentile 
17 2.00 4.00 6.50 
Platelet count (x 
10 9/l) 
<75. 
Percentile 
111 176.00 212.00 255.00 
0.263 
>75 
percentile 
37 165.50 196.00 241.00 
Fibrinogen (g/l) 
<75. 
Percentile 
111 3.30 3.90 4.60 
0.203 
>75 
percentile 
37 3.10 3.60 4.35 
Hemoglobin 
<75. 
Percentile 
111 121.00 133.00 145.00 
0.183 
>75 
percentile 
37 126.00 140.00 146.00 
Hematocrit 
<75. 
Percentile 
111 0.37 0.40 0.43 0.183 
>75 
percentile 
37 0.38 0.42 0.44 
INR 
<75. 
Percentile 
111 0.94 0.98 1.06 
0.245 
>75 
percentile 
37 0.93 0.96 1.01 
Cross-clamp 
time (min) 
<75. 
Percentile 
111 49.00 67.00 88.00 
0.473 
>75 
percentile 
37 50.00 69.00 104.50 
Cardiopulmonary 
bypass time 
(min) 
<75. 
Percentile 
111 74.00 96.00 126.00 
0.089 
>75 
percentile 
37 80.50 112.00 139.50 
Ventilation (h) 
<75. 
Percentile 
110 7.75 9.00 12.00 
0.24 
>75 
percentile 
36 7.00 10.00 15.75 
 
 Table 1b: 
 
24 hour chest tube output (ml/kg) 
Chi 
Square <75. percentile 
N=111 
>75. percentile 
N=37 
N % N % p 
Gender 
Male 79 71.2% 26 70.3% 
0.917 
Female 32 28.8% 11 29.7% 
Arterial 
hypertension 
No 18 16.2% 7 18.9% 
0.704 
Yes 93 83.8% 30 81.1% 
Diabetes 
mellitus 
No 76 68.5% 27 73.0% 
0.606 
Yes 35 31.5% 10 27.0% 
Smoking 
habit 
No 88 79.3% 30 81.1% 
0.813 
Yes 23 20.7% 7 18.9% 
Renal 
dysfunction  
No 109 98.2% 35 94.6% 
0.242 
Yes 2 1.8% 2 5.4% 
Beta blockers 
No 28 25.2% 7 18.9% 
0.434 
Yes 83 74.8% 30 81.1% 
Amiodarone 
No 99 89.2% 33 89.2% 
1 
Yes 12 10.8% 4 10.8% 
Calcium 
channel 
blockers 
No 81 73.0% 25 67.6% 
0.528 
Yes 30 27.0% 12 32.4% 
Clopidogrel 
No 86 77.5% 21 56.8% 
0.015 
Yes 25 22.5% 16 43.2% 
acetylsalicylic 
acid 
No 41 36.9% 13 35.1% 
0.844 
Yes 70 63.1% 24 64.9% 
Antiplatelet 
therapy 
No 35 31.5% 9 24.3% 
0.406 
Yes 76 68.5% 28 75.7% 
Lipid 
lowering 
drugs 
No 28 25.2% 13 35.1% 
0.243 
Yes 83 74.8% 24 64.9% 
Procedure 
type 
Isolated 
CABG 
62 55.9% 22 59.5% 
0.257 
Valve 
procedure 
27 24.3% 7 18.9% 
Combined 
procedure 
11 9.9% 7 18.9% 
Other 11 9.9% 1 2.7% 
ISOLATED 
CABG 
Other 49 44.1% 15 40.5% 
0.702 Isolated 
CABG 
62 55.9% 22 59.5% 
 
 Table 2: 
Transfusion and clinical outcomes of patient groups according to bleeding tendency 
 
CTO 24h (ml/kg)   
<75. percentile 
N=111 
>75. percentile 
N=37 
Chi square 
N % N % p 
Transfuded 
fresh frozen 
plasma 
No 97 87.4% 21 56.8% 
<0.001 
Yes 14 12.6% 16 43.2% 
Transfuded 
packed red 
blood cells 
No 24 21.6% 5 13.5% 
0.282 
Yes 87 78.4% 32 86.5% 
Transfuded 
Fibrinogen 
concentrate 
No 109 98.2% 28 75.7% 
<0.001 
Yes 2 1.8% 9 24.3% 
Transfuded 
platelet 
concentrate 
No 109 98.2% 33 89.2% 
0.016 
Yes 2 1.8% 4 10.8% 
30 day 
mortality 
Alive 110 99.1% 35 94.6% 
0.092 
Dead 1 0.9% 2 5.4% 
1 year 
mortality 
Alive 103 98.1% 29 87.9% 
0.012 
Dead 2 1.9% 4 12.1% 
1 year re-
hospitalization 
No 88 83.8% 27 81.8% 
0.789 
Yes 17 16.2% 6 18.2% 
  
24 hours 
chest 
tube 
output 
(ml/kg) 
n 
25th 
percentile 
50th 
(Median) 
75th 
percentile 
Mann-
Whitney U 
Ventilation 
(h) 
<75. 
percentile 
110 7.75 9.00 12.00 
0.24 
>75 
percentile 
36 7.00 10.00 15.75 
ICU stay 
(days) 
<75. 
percentile 
111 2.00 2.00 3.00 
0.489 
>75 
percentile 
37 1.00 2.00 3.50 
Postoperative 
hospital stay 
(days) 
<75. 
percentile 
111 7.00 7.00 9.00 
0.84 
>75 
percentile 
37 6.50 7.00 10.00 
 Table 3 
Table 3a:  
Comparison of the multiple electrode aggregometry and rotational thromboelastometry results 
between groups with respect to bleeding tendency and correlations of parameters with 24 
hours chest tube output (ml/kg). Results of  tests are observed prior to induction of anesthesia 
(T1).
  
According to 24 hour chest tube output (mL/kg) 
 
CTO 24 H mL/kg 
T1 BLEEDER NON-BLEEDER Mann-Whitney U p 
Spearman r P 
  
25th percentile Median 75th percentile 25th percentile Median 75th percentile P 
ASPI (AUC) 12 20 53 21 40 67 0.043 -0.193 0.019 
ADP (AUC) 57 72 89 63 77 93 0.265 -0.095 0.252 
TRAP (AUC) 95 105 120 95 109 122 0.849 -0.118 0.153 
EXTEM CT (sec) 60 65 71 54 60 70 0.120 0.099 0.231 
EXTEM CFT (sec) 65 77 93 58 73 89 0.233 0.115 0.166 
EXTEM alfa (degree) 72 76 80 73 76 80 0.701 -0.102 0.218 
EXTEM A 10 (mm) 56 60 62 57 61 66 0.191 -0.150 0.069 
EXTEM A 20 (mm) 62 66 68 63 67 71 0.190 -0.157 0.056 
EXTEM A 30 (mm) 64 67 69 63 68 72 0.296 -0.143 0.082 
INTEM CT (sec) 150 164 191 147 169 200 0.820 -0.076 0.356 
INTEM CFT (sec) 63 70 79 54 65 84 0.333 0.143 0.083 
INTEM ALFA (degree) 74 76 78 75 77 80 0.173 -0.151 0.066 
INTEM A 10 (mm) 54 57 60 54 59 64 0.177 -0.157 0.057 
INTEM A 20 (mm) 60 63 66 60 65 69 0.112 -0.171 0.038 
INTEM A 30 (mm) 60 64 67 61 65 69 0.134 -0.174 0.035 
FIBTEM CT (sec) 50 55 59 48 53 58 0.346 0.093 0.260 
FIBTEM A 10 (mm) 13 15 19 14 17 22 0.093 -0.190 0.021 
FIBTEM A 20 (mm) 14 16 20 15 18 24 0.044 -0.210 0.010 
FIBTEM A 30 (mm) 14 17 20 15 19 24 0.062 -0.193 0.019 
Table 3b: 
Comparison of the multiple electrode aggregometry and rotational thromboelastometry results 
between groups with respect to bleeding tendency and correlations of parameters with 24 hours 
chest tube output (ml/kg). Results of tests are during cardiopulmonary bypass after aortic cross 
clamp removal.
   
According to 24 hour chest tube output (mL/kg) CTO 24 H mL/kg 
T2 BLEEDER NON-BLEEDER Mann-Whitney U 
Spearman r p 
  
25th percentile Median 75th percentile 25th percentile Median 75th percentile p 
ASPI (AUC) 4 9 13 6 15 33 0.004 -0.203 0.013 
ADP (AUC) 23 30 46 29 48 67 0.002 -0.230 0.005 
TRAP (AUC) 73 109 128 92 116 142 0.098 -0.130 0.115 
EXTEM CT (sec) 64 73 87 66 76 90 0.609 -0.048 0.563 
EXTEM CFT (sec) 114 139 165 95 118 144 0.004 0.272 0.001 
EXTEM alfa (degree) 62 67 69 65 69 74 0.010 -0.245 0.003 
EXTEM A 10 (mm) 41 44 48 45 49 54 0.001 -0.308 <0.001 
EXTEM A 20 (mm) 48 52 56 53 57 61 0.001 -0.301 <0.001 
EXTEM A 30 (mm) 50 55 59 56 59 63 <0.001 -0.311 <0.001 
HEPTEM CT (sec) 187 200 221 175 200 223 0.825 0.043 0.602 
HEPTEM CFT (sec) 99 130 161 84 102 124 0.001 0.261 0.001 
HEPTEM ALFA (degree) 64 68 72 68 72 76 0.013 -0.199 0.015 
HEPTEM A 10 (mm) 39 44 47 44 48 52 <0.001 -0.329 <0.001 
HEPTEM A 20 (mm) 46 51 54 51 55 59 <0.001 -0.322 <0.001 
HEPTEM A 30 (mm) 50 53 56 53 57 62 <0.001 -0.331 <0.001 
FIBTEM CT (sec) 59 64 72 62 67 81 0.111 -0.154 0.061 
FIBTEM A 10 (mm) 7 9 12 8 11 14 0.044 -0.236 0.004 
FIBTEM A 20 (mm) 8 10 12 9 12 15 0.029 -0.223 0.007 
FIBTEM A 30 (mm) 8 10 12 9 12 16 0.002 -0.282 0.001 
Table 3c: 
Comparison of the multiple electrode aggregometry and rotational thromboelastometry results 
between groups with respect to bleeding tendency and correlations of parameters with 24 hours 
chest tube output (ml/kg). Blood sampling was performed 15 min after protamine administration. 
   
According to 24 hour chest tube output (mL/kg) CTO 24 H mL/kg 
T3 BLEEDER NON-BLEEDER Mann-Whitney U 
Spearman r p 
  
25th percentile Median 75th percentile 25th percentile Median 75th percentile p 
ASPI (AUC) 8 14 22 10 27 51 0.013 -0.236 0.004 
ADP (AUC) 15 22 36 22 41 66 0.002 -0.299 <0.001 
TRAP (AUC) 78 93 113 77 103 133 0.133 -0.144 0.081 
EXTEM CT (sec) 72 83 96 68 77 94 0.197 0.191 0.020 
EXTEM CFT (sec) 131 166 212 105 141 172 0.005 0.271 0.001 
EXTEM alfa (degree) 53 59 64 59 66 73 0.001 -0.317 <0.001 
EXTEM A 10 (mm) 36 42 47 41 46 52 0.005 -0.280 0.001 
EXTEM A 20 (mm) 45 51 55 49 54 60 0.005 -0.284 <0.001 
EXTEM A 30 (mm) 48 53 57 52 56 61 0.005 -0.295 <0.001 
HEPTEM CT (sec) 190 209 230 160 183 205 <0.001 0.348 <0.001 
HEPTEM CFT (sec) 126 164 227 105 132 176 0.006 0.254 0.002 
HEPTEM ALFA (degree) 55 62 66 60 67 72 0.004 -0.278 0.001 
HEPTEM A 10 (mm) 33 39 43 38 43 47 0.002 -0.289 <0.001 
HEPTEM A 20 (mm) 40 46 50 45 50 54 0.002 -0.322 <0.001 
HEPTEM A 30 (mm) 44 48 52 47 52 55 0.003 -0.329 <0.001 
FIBTEM CT (sec) 68 75 85 57 65 86 0.012 0.240 0.003 
FIBTEM A 10 (mm) 5 8 9 7 9 13 0.002 -0.313 <0.001 
FIBTEM A 20 (mm) 6 8 10 8 11 14 0.001 -0.354 <0.001 
FIBTEM A 30 (mm) 6 8 11 8 11 14 <0.001 -0.377 <0.001 
 
Figures 
 
Figure 1.  
Receiver operating characteristic curve analysis for excessive bleeding prediction by the Multiplate 
ASPI test after protamine administration. The best predictive value corresponds to an ASPI test 
value of equal or less than 22 AUC (Area under the curve 0.636. 95% Confidence Interval 0.553-
0.714. p=0.008). 
 
 
 
 
Figure 2.  
Receiver operating characteristic curve analysis for excessive bleeding prediction by the Multiplate 
ADP test after protamine administration. The best predictive value corresponds to an ADP test 
value of equal or less than 36 AUC (Area under the curve 0.667. 95% Confidence Interval 0.585-
0.742. p=0.001). 
 
 
 
 
 
 
Figure 3.  
Receiver operating characteristic curve analysis for excessive bleeding prediction by the TEM 
ExTEM test. The best predictive value corresponds to an ExTEM alfa angle value of equal or less 
than 63 degrees (Area under the curve 0.691. 95% Confidence Interval 0.610-0.764. p<0.001). 
 
 
 
 
 
 
 
 
Figure 4.  
Receiver operating characteristic curve analysis for excessive bleeding prediction by the TEM 
FibTEM test. The best predictive value corresponds to a FibTEM A 30 value of equal or less than 
11 mm (Area under the curve 0.695. 95% Confidence Interval 0.614-0.768. p<0.001). 
 
 
 
 
 
 
 
Figure 5.  
Receiver operating characteristic curve analysis for excessive bleeding prediction by the TEM 
HepTEM test. The best predictive value corresponds to a HepTEM A 30 value of equal or less than 
61 mm (Area under the curve 0.663. 95% Confidence Interval 0.580-0.738. p=0.002). 
 
 
